Abstract:Key Points A large fraction of point mutations that cause genetic diseases affect splicing efficiency and/or accuracy. Most of these mutations directly affect the canonical consensus sequences that define exon–intron boundaries, and are therefore correctly identified as 'splicing mutations'. Information that is present in the coding regions of genes also contributes to the correct identification of exon–intron boundaries. For example, exonic splicing enhancer (ESE) and silencer (ESS) elements are very prevalent and might be present in most, if not all, constitutive and alternative exons. ESEs are recognized by a class of splicing factors, the SR proteins, that promote splicing by recruiting spliceosomal components to the correct splice sites and/or by antagonizing the action of nearby silencers. Several classes of ESEs, which are recognized by different SR proteins, have been identified, and computational tools are being developed to predict the location, specificity and efficiency of putative ESEs. Because ESEs are embedded in protein-coding sequences, some nonsense, missense and translationally silent point mutations have actually been misclassified. Those mutations that inactivate an ESE can result in partial or complete exon skipping, and can therefore markedly affect the structure or amounts of the expressed protein product. An increasing proportion of point mutations are being reported to affect pre-mRNA splicing. Although reading-frame-dependent mechanisms have been proposed to account for nonsense-associated altered splicing (NAS), in most cases the disruption of ESEs or of RNA secondary structures that are required for proper splicing seems to be the mechanism that leads to exon skipping, regardless of the type of point mutation. Some coding single-nucleotide polymorphisms (cSNPs) can be expected likewise to disrupt elements that are involved in splicing and to exert a subtle effect on splice-site selection, thereby contributing to phenotypic variability, to the variable penetrance of mutations elsewhere in the gene and to cell-type-specific differences in gene expression. The effects of point mutations should be routinely analysed at the mRNA level before drawing conclusions about the importance of the affected amino acid, as their correct classification in terms of the actual mechanism of gene inactivation is essential for understanding structure–function relationships in the corresponding protein, for assessing the phenotypic risk in individuals with familial disease predispositions and for devising new therapies.

Regional nonsense constraint offers clinical and biological insights into rare genetic disorders

Systematic analysis of nonsense variants uncovers peptide release rate as a novel modifier of nonsense-mediated mRNA decay efficiency

The landscape of regional missense mutational intolerance quantified from 125,748 exomes

Genetic constraint at single amino acid resolution in protein domains improves missense variant prioritisation and gene discovery

Readthrough Approach Using NV Translational Readthrough-Inducing Drugs (TRIDs): A Study of the Possible Off-Target Effects on Natural Termination Codons (NTCs) on TP53 and Housekeeping Gene Expression

The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy

Systematic analysis of variants escaping nonsense-mediated decay uncovers candidate Mendelian diseases

Physiological Consequences of Nonsense-Mediated Decay and Its Role in Adaptive Responses

Regsnps: a Strategy for Prioritizing Regulatory Single Nucleotide Substitutions.

Nonsense-mediated Mrna Decay and Human Monogenic Disease

Therapeutic Nonsense Suppression Modalities: From Small Molecules to Nucleic Acid-Based Approaches

Translation velocity determines the efficacy of engineered suppressor tRNAs on pathogenic nonsense mutations

Variable efficiency of nonsense-mediated mRNA decay across human tissues, tumors and individuals

PTC124 Targets Genetic Disorders Caused by Nonsense Mutations.

Prioritizing De Novo Potential Non-Canonical Splicing Variants in Neurodevelopmental Disorders

Listening to silence and understanding nonsense: exonic mutations that affect splicing

Regional Variation in Cardiovascular Genes Enables a Tractable Genome Editing Strategy

Investigating the role of common cis-regulatory variants in modifying penetrance of putatively damaging, inherited variants in severe neurodevelopmental disorders

StopKB: a comprehensive knowledgebase for nonsense suppression therapies

Improved diagnosis of rare disease patients through application of constrained coding region annotation and de novo status.

Nonsense suppression by near-cognate tRNAs employs alternative base pairing at codon positions 1 and 3